VAN DER HEYDEN et al U.S. National Phase of PCT/EP2003/009790

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (original) A composition comprising an insulin sensitizer and a peptide fraction.
- 2. (original) A composition according to claim 1, wherein the peptide fraction is part of a hydrolysate.
- 3. (currently amended) A composition according to claim 1 or 2, wherein the peptide fraction comprises an amount of at least one free amino acid which is any of leucine, phenylalanine and arginine.
- 4. (currently amended) A composition according to any one of claims 1 to 3 claim 1 wherein the peptides of the peptide fraction are protein molecules having a molecular weight of less than 2000Da.
- 5. (currently amended) A composition according to any one of the claims 1 to 4 claim 1 wherein the peptide fraction is rich in peptides having a molecular weight below 500Da preferably rich in di and/or tripeptides.
- 6. (original) A composition according to claim 5 wherein at least 20 molar%, at least 25 molar% or at least 30 molar% or at least 35 molar% of the peptides with a molecular weight below 2000Da, is present as di and/or tripeptide.
- 7. (currently amended) A composition according to claim 5 or 6, wherein the diamd/or tripeptides are rich in proline at one end of the peptide.
- 8. (currently amended) A composition according to any one of claim 5 to 7 claim 5, wherein at least 20%, at least 30% or at least 40% of the proline present in the starting protein is present in the di and/or tripeptides.

VAN DER HEYDEN et al U.S. National Phase of PCT/EP2003/009790

- 9. (currently amended) A composition according to any one of claims 5 to 8 claim 5, wherein 30% of the tripeptides or 35% of the tripeptides have a carboxy terminal proline.
- 10. (currently amended) A composition according to any one of claims 5 to 9 claim 5, wherein at least 30 molar% of the peptides or at least 50 molar% or at least 70 molar% of all peptides present with a molecular weight below 2000 Da.
- 11. (currently amended) A composition according to any one of claims 1 to 10 claim 1, wherein the insulin sensitizer is chromium, vanadium, niacin, corosilic acid, banana leafextract, ginseng berry, Ginsensoside Re, cinnamon, methylhydroxy chalcone polymer, pterostilbene, biguanide or thiazolidinedione.
- 12. (currently amended) A dietic product, a pharmaceutical product, or a food or a food supplement comprising the composition according to any one of claims 1 to 11 claim 1.
- 13. (currently amended) A composition according to any one of claims 1 to 11 claim 1 for use in a method of treatment of the human or animal body by therapy or diagnosis.
- 14. (currently amended) Use of a composition according to any one of claims 1 to 11 claim 1 for the manufacture of a medicament for treating type 2 diabetes or preventing diabetes.
- 15. (original) Use of a composition comprising a peptide fraction for the manufacture of a medicament for treating type 2 diabetes or preventing diabetes.
- 16. (original) Use according to claim 15, wherein the peptide fraction comprises at least one free amino acid which is one of tyrosine, leucine, phenylamine and arginine.
- 17. (currently amended) Method of treatment of type 2 diabetes which comprises the use of a composition according any one of claims 1 to 11 claim 1.
- 18. (currently amended) Method of preventing diabetes which comprises the use of a composition according to any one of claims 1 to 11 claim 1